Creo Medical Group PLC (CREO) - Net Assets

Latest as of June 2025: GBX60.90 Million GBX ≈ $7.41K USD

Based on the latest financial reports, Creo Medical Group PLC (CREO) has net assets worth GBX60.90 Million GBX (≈ $7.41K USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX68.80 Million ≈ $8.37K USD) and total liabilities (GBX7.90 Million ≈ $961.20 USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check CREO asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets GBX60.90 Million
% of Total Assets 88.52%
Annual Growth Rate N/A
5-Year Change -32.49%
10-Year Change 2502.55%
Growth Volatility 390.76

Creo Medical Group PLC - Net Assets Trend (2005–2024)

This chart illustrates how Creo Medical Group PLC's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Creo Medical Group PLC for the complete picture of this company's asset base.

Annual Net Assets for Creo Medical Group PLC (2005–2024)

The table below shows the annual net assets of Creo Medical Group PLC from 2005 to 2024. For live valuation and market cap data, see Creo Medical Group PLC (CREO) market capitalisation.

Year Net Assets Change
2024-12-31 GBX42.40 Million
≈ $5.16K		 -29.10%
2023-12-31 GBX59.80 Million
≈ $7.28K		 +21.05%
2022-12-31 GBX49.40 Million
≈ $6.01K		 -32.62%
2021-12-31 GBX73.32 Million
≈ $8.92K		 +16.74%
2020-12-31 GBX62.81 Million
≈ $7.64K		 -24.02%
2019-12-31 GBX82.66 Million
≈ $10.06K		 +73.25%
2018-12-31 GBX47.71 Million
≈ $5.81K		 +551.03%
2018-06-30 GBX7.33 Million
≈ $891.73		 -49.98%
2017-06-30 GBX14.65 Million
≈ $1.78K		 +799.39%
2016-06-30 GBX1.63 Million
≈ $198.22		 -49.44%
2016-02-29 GBX3.22 Million
≈ $392.03		 +330.52%
2015-02-28 GBX748.41K
≈ $91.06		 -45.56%
2014-02-28 GBX1.37 Million
≈ $167.26		 +1116.51%
2008-02-29 GBX113.00K
≈ $13.75		 +841.67%
2007-02-28 GBX12.00K
≈ $1.46		 +500.00%
2006-02-28 GBX-3.00K
≈ $-0.37		 +75.00%
2005-02-28 GBX-12.00K
≈ $-1.46		 --

Equity Component Analysis

This analysis shows how different components contribute to Creo Medical Group PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 1442600.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock GBX400.00K 0.94%
Other Comprehensive Income GBX23.10 Million 54.48%
Other Components GBX192.00 Million 452.83%
Total Equity GBX42.40 Million 100.00%

Creo Medical Group PLC Competitors by Market Cap

The table below lists competitors of Creo Medical Group PLC ranked by their market capitalization.

Company Market Cap
Midsona AB (publ)
ST:MSON-A
 $633.92K
R.E.A. Holdings plc
LSE:RE
 $637.29K
Jersey Electricity plc
LSE:JEL
 $637.31K
Tian Ruixiang Holdings Ltd
NASDAQ:TIRX
 $637.69K
CERo Therapeutics Holdings, Inc. Common Stock
NASDAQ:CERO
 $628.86K
Newtopia Inc
V:NEWU
 $626.69K
Schroder British Opportunities Trus
LSE:SBO
 $624.91K
Antelope Enterprise Holdings Ltd
NASDAQ:AEHL
 $621.24K

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Creo Medical Group PLC's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 59,800,000 to 42,400,000, a change of -17,400,000 (-29.1%).
  • Net loss of 28,700,000 reduced equity.
  • New share issuances of 11,100,000 increased equity.
  • Other comprehensive income increased equity by 199,999.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income GBX-28.70 Million -67.69%
Share Issuances GBX11.10 Million +26.18%
Other Comprehensive Income GBX200.00K +0.47%
Other Changes GBX1.00 +0.0%
Total Change GBX- -29.10%

Book Value vs Market Value Analysis

This analysis compares Creo Medical Group PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 107.69x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 769.07x to 107.69x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2014-02-28 GBX0.02 GBX12.63 x
2015-02-28 GBX0.01 GBX12.63 x
2016-02-29 GBX0.04 GBX12.63 x
2017-06-30 GBX0.24 GBX12.63 x
2018-06-30 GBX0.09 GBX12.63 x
2018-12-31 GBX0.51 GBX12.63 x
2019-12-31 GBX0.66 GBX12.63 x
2020-12-31 GBX0.39 GBX12.63 x
2021-12-31 GBX0.43 GBX12.63 x
2022-12-31 GBX0.26 GBX12.63 x
2023-12-31 GBX0.19 GBX12.63 x
2024-12-31 GBX0.12 GBX12.63 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Creo Medical Group PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -67.69%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -717.50%
  • • Asset Turnover: 0.06x
  • • Equity Multiplier: 1.53x
  • Recent ROE (-67.69%) is above the historical average (-82.78%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2014 -123.43% -211.43% 0.49x 1.18x GBX-1.83 Million
2015 -318.28% 0.00% 0.00x 1.40x GBX-2.46 Million
2016 -103.34% -622.74% 0.14x 1.17x GBX-3.65 Million
2016 -99.02% -317.43% 0.21x 1.48x GBX-1.78 Million
2017 -53.00% 0.00% 0.00x 1.10x GBX-9.23 Million
2018 -114.73% 0.00% 0.00x 1.31x GBX-9.14 Million
2018 -20.69% 0.00% 0.00x 1.04x GBX-14.64 Million
2019 -19.25% -118096.56% 0.00x 1.07x GBX-24.18 Million
2020 -32.35% -215.46% 0.10x 1.47x GBX-26.60 Million
2021 -33.55% -97.75% 0.25x 1.37x GBX-31.93 Million
2022 -54.52% -99.14% 0.36x 1.52x GBX-31.88 Million
2023 -36.29% -70.45% 0.40x 1.28x GBX-27.68 Million
2024 -67.69% -717.50% 0.06x 1.53x GBX-32.94 Million

Industry Comparison

This section compares Creo Medical Group PLC's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

  • Industry: Medical Devices
  • Average net assets among peers: $47,335,537
  • Average return on equity (ROE) among peers: -6.02%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Creo Medical Group PLC (CREO) GBX60.90 Million -123.43% 0.13x $633.60K
AOTI Inc (AOTI) $3.41 Million 51.02% 1.74x $891.93K
EKF Diagnostics Holdings Plc (EKF) $-3.03 Million 0.00% 0.00x $1.39 Million
Inspiration Healthcare Group PLC (IHC) $1.65 Million 0.00% 0.38x $322.92K
NIOX Group PLC (NIOX) $81.90 Million 19.66% 0.20x $3.41 Million
Polarean Imaging Plc (POLX) $8.73 Million -75.05% 0.25x $11.75K
Rua Life Sciences PLC (RUA) $8.51 Million -17.06% 0.19x $147.24K
Smith & Nephew PLC (SN) $273.58 Million 25.01% 1.35x $118.48 Million
Surgical Innovations Group plc (SUN) $3.93 Million -51.73% 0.98x $51.07K

About Creo Medical Group PLC

LSE:CREO UK Medical Devices
Market Cap
$633.60K
GBX5.21 Billion GBX
Market Cap Rank
#30447 Global
#871 in UK
Share Price
GBX12.63
Change (1 day)
-2.88%
52-Week Range
GBX9.90 - GBX17.75
All Time High
GBX243.00
Categories
Companies in UK Medical Devices
About

Creo Medical Group PLC, through its subsidiaries, engages in the research, development, manufacture, and sale of medical devices and instruments for clinics and hospitals in the United Kingdom. It develps CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with controllable devices deli… Read more